Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Reform 101: Cashing In On Hidden Financial Aid Provisions

Executive Summary

Biopharmas could win grants equivalent to half of their research expenses in 2009 and 2010, plus apply for a slice of the $500 million in new R&D funding available in areas of high medical need, courtesy of the health reform package

You may also be interested in...



Limited Funding For Cures Acceleration Network Has Upside: Partnership Options

Congressional appropriations provide $10 million for the new program to speed development of therapies for “high need” diseases and conditions, substantially less than the $100 million requested by NIH.

NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates

A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.

NIH Center Would Seek To Boost “Repurposing” Of Shelved Drug Candidates

A proposed new center at the National Institutes of Health dedicated to speeding “translation” of biomedical research into therapies may focus initially on exploring new uses for drug candidates shelved by pharmaceutical firms, according to NIH Director Francis Collins.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel